Suchergebnisse - "Momtaz, Parisa"

Neoadjuvant relatlimab and nivolumab in resectable melanoma von Amaria, Rodabe N., Postow, Michael, Burton, Elizabeth M., Tetzlaff, Michael T., Ross, Merrick I., Torres-Cabala, Carlos, Glitza, Isabella C., Duan, Fei, Milton, Denái R., Busam, Klaus, Simpson, Lauren, McQuade, Jennifer L., Wong, Michael K., Gershenwald, Jeffrey E., Lee, Jeffrey E., Goepfert, Ryan P., Keung, Emily Z., Fisher, Sarah B., Betof-Warner, Allison, Shoushtari, Alexander N., Callahan, Margaret, Coit, Daniel, Bartlett, Edmund K., Bello, Danielle, Momtaz, Parisa, Nicholas, Courtney, Gu, Aidi, Zhang, Xuejun, Korivi, Brinda Rao, Patnana, Madhavi, Patel, Sapna P., Diab, Adi, Lucci, Anthony, Prieto, Victor G., Davies, Michael A., Allison, James P., Sharma, Padmanee, Wargo, Jennifer A., Ariyan, Charlotte, Tawbi, Hussein A.

“… Relatlimab and nivolumab combination immunotherapy improves progression-free survival over nivolumab monotherapy in patients with unresectable advanced …”
Volltext

Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade von Bello, Danielle M., Panageas, Katherine S., Hollmann, Travis, Shoushtari, Alexander N., Momtaz, Parisa, Chapman, Paul B., Postow, Michael A., Callahan, Margaret K., Wolchok, Jedd D., Brady, Mary S., Coit, Daniel G., Ariyan, Charlotte E.

“… Introduction Checkpoint inhibitors have improved outcomes in metastatic melanoma, with 4-year overall survival (OS) of 46% for anti-PD-1 alone or 53% in …”
Volltext

Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis von Kuk, Deborah, Shoushtari, Alexander N., Barker, Christopher A., Panageas, Katherine S., Munhoz, Rodrigo R., Momtaz, Parisa, Ariyan, Charlotte E., Brady, Mary Sue, Coit, Daniel G., Bogatch, Kita, Callahan, Margaret K., Wolchok, Jedd D., Carvajal, Richard D., Postow, Michael A.

“… Background. Subtypes of melanoma, such as mucosal, uveal, and acral, are believed to result in worse prognoses than nonacral cutaneous melanoma. After a …”
Volltext

Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma von Shoushtari, Alexander N, Friedman, Claire F, Navid-Azarbaijani, Pedram, Postow, Michael A, Callahan, Margaret K, Momtaz, Parisa, Panageas, Katherine S, Wolchok, Jedd D, Chapman, Paul B

“… Nivolumab plus ipilimumab (nivo + ipi) is a standard treatment of advanced melanoma. Two randomized trials describe high objective response rates by Response …”
Weitere Angaben

Immunologic correlates in a CIC::DUX4 fusion-positive sarcoma responsive to dual immune checkpoint blockade von Babatunde, Olayode O., Coca Membribes, Sara, Anthonescu, Cristina, Bradic, Martina, O’Malley, Bernard, Linkov, Irina, Bartlett, Edmund, Momtaz, Parisa, Alektiar, Kaled, Gounder, Mrinal M., Rosenbaum, Evan, Tap, William D., D’Angelo, Sandra P., Kelly, Ciara M.

“… CIC::DUX4 sarcoma (CDS) is a rare and aggressive subtype of soft tissue sarcoma with poor prognosis and limited treatment options. Immunotherapy has not been …”
Volltext

Hepatic veno-occlusive disease: pathogenesis, diagnosis and treatment von Wadleigh, Martha, Ho, Vincent, Momtaz, Parisa, Richardson, Paul

“… Hepatic veno-occlusive disease (VOD) is one of the most serious complications following hematopoietic stem cell transplantation (SCT) and is associated with a …”
Weitere Angaben

Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease and Multiorgan Failure after Stem Cell Transplantation: A Multicenter, Randomized, Dose-Finding Trial von Richardson, Paul G., Soiffer, Robert J., Antin, Joseph H., Uno, Hajime, Jin, Zhezhen, Kurtzberg, Joanne, Martin, Paul L., Steinbach, Gideon, Murray, Karen F., Vogelsang, Georgia B., Chen, Allen R., Krishnan, Amrita, Kernan, Nancy A., Avigan, David E., Spitzer, Thomas R., Shulman, Howard M., Di Salvo, Donald N., Revta, Carolyn, Warren, Diane, Momtaz, Parisa, Bradwin, Gary, Wei, L.J., Iacobelli, Massimo, McDonald, George B., Guinan, Eva C.

“… Therapeutic options for severe hepatic veno-occlusive disease (VOD) are limited and outcomes are dismal, but early phase I/II studies have suggested promising …”
Volltext

Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer von Rojas, Luis A., Sethna, Zachary, Soares, Kevin C., Olcese, Cristina, Pang, Nan, Patterson, Erin, Lihm, Jayon, Ceglia, Nicholas, Guasp, Pablo, Chu, Alexander, Yu, Rebecca, Chandra, Adrienne Kaya, Waters, Theresa, Ruan, Jennifer, Amisaki, Masataka, Zebboudj, Abderezak, Odgerel, Zagaa, Payne, George, Derhovanessian, Evelyna, Müller, Felicitas, Rhee, Ina, Yadav, Mahesh, Dobrin, Anton, Sadelain, Michel, Łuksza, Marta, Cohen, Noah, Tang, Laura, Basturk, Olca, Gönen, Mithat, Katz, Seth, Do, Richard Kinh, Epstein, Andrew S., Momtaz, Parisa, Park, Wungki, Sugarman, Ryan, Varghese, Anna M., Won, Elizabeth, Desai, Avni, Wei, Alice C., D’Angelica, Michael I., Kingham, T. Peter, Mellman, Ira, Merghoub, Taha, Wolchok, Jedd D., Sahin, Ugur, Türeci, Özlem, Greenbaum, Benjamin D., Jarnagin, William R., Drebin, Jeffrey, O’Reilly, Eileen M., Balachandran, Vinod P.

“… Pancreatic ductal adenocarcinoma (PDAC) is lethal in 88% of patients 1 , yet harbours mutation-derived T cell neoantigens that are suitable for vaccines 2 , 3 …”
Volltext

Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade von Betof Warner, Allison, Palmer, Jessica S, Shoushtari, Alexander N, Goldman, Debra A, Panageas, Katherine S, Hayes, Sara A, Bajwa, Raazi, Momtaz, Parisa, Callahan, Margaret K, Wolchok, Jedd D, Postow, Michael A, Chapman, Paul B

“… To analyze long-term outcomes after treatment discontinuation of anti-programmed death-1 (anti-PD-1) therapy in a cohort of patients with melanoma with the …”
Weitere Angaben

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center von Horvat, Troy Z, Adel, Nelly G, Dang, Thu-Oanh, Momtaz, Parisa, Postow, Michael A, Callahan, Margaret K, Carvajal, Richard D, Dickson, Mark A, D'Angelo, Sandra P, Woo, Kaitlin M, Panageas, Katherine S, Wolchok, Jedd D, Chapman, Paul B

“… Ipilimumab is a standard treatment for metastatic melanoma, but immune-related adverse events (irAEs) are common and can be severe. We reviewed our large, …”
Weitere Angaben

First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial von Janjigian, Yelena Y, Maron, Steven B, Chatila, Walid K, Millang, Brittanie, Chavan, Shweta S, Alterman, Carly, Chou, Joanne F, Segal, Michal F, Simmons, Marc Z, Momtaz, Parisa, Shcherba, Marina, Ku, Geoffrey Y, Zervoudakis, Alice, Won, Elizabeth S, Kelsen, David P, Ilson, David H, Nagy, Rebecca J, Lanman, Richard B, Ptashkin, Ryan N, Donoghue, Mark T A, Capanu, Marinela, Taylor, Barry S, Solit, David B, Schultz, Nikolaus, Hechtman, Jaclyn F

“… Addition of trastuzumab to first-line chemotherapy improves overall survival in patients with HER2-positive metastatic gastric cancer. We assessed the safety …”
Volltext

RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer von Sethna, Zachary, Guasp, Pablo, Reiche, Charlotte, Milighetti, Martina, Ceglia, Nicholas, Patterson, Erin, Lihm, Jayon, Payne, George, Lyudovyk, Olga, Rojas, Luis A., Pang, Nan, Ohmoto, Akihiro, Amisaki, Masataka, Zebboudj, Abderezak, Odgerel, Zagaa, Bruno, Emmanuel M., Zhang, Siqi Linsey, Cheng, Charlotte, Elhanati, Yuval, Derhovanessian, Evelyna, Manning, Luisa, Müller, Felicitas, Rhee, Ina, Yadav, Mahesh, Merghoub, Taha, Wolchok, Jedd D., Basturk, Olca, Gönen, Mithat, Epstein, Andrew S., Momtaz, Parisa, Park, Wungki, Sugarman, Ryan, Varghese, Anna M., Won, Elizabeth, Desai, Avni, Wei, Alice C., D’Angelica, Michael I., Kingham, T. Peter, Soares, Kevin C., Jarnagin, William R., Drebin, Jeffrey, O’Reilly, Eileen M., Mellman, Ira, Sahin, Ugur, Türeci, Özlem, Greenbaum, Benjamin D., Balachandran, Vinod P.

“… A fundamental challenge for cancer vaccines is to generate long-lived functional T cells that are specific for tumour antigens. Here we find that mRNA–lipoplex …”
Volltext

LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade von Shen, Ronglai, Postow, Michael A, Adamow, Matthew, Arora, Arshi, Hannum, Margaret, Maher, Colleen, Wong, Phillip, Curran, Michael A, Hollmann, Travis J, Jia, Liwei, Al-Ahmadie, Hikmat, Keegan, Niamh, Funt, Samuel A, Iyer, Gopa, Rosenberg, Jonathan E, Bajorin, Dean F, Chapman, Paul B, Shoushtari, Alexander N, Betof, Allison S, Momtaz, Parisa, Merghoub, Taha, Wolchok, Jedd D, Panageas, Katherine S, Callahan, Margaret K

“… Immune checkpoint blocking antibodies are a cornerstone in cancer treatment; however, they benefit only a subset of patients and biomarkers to guide immune …”
Weitere Angaben

Therapeutic Implications of Detecting MAPK-Activating Alterations in Cutaneous and Unknown Primary Melanomas von Shoushtari, Alexander N, Chatila, Walid K, Arora, Arshi, Sanchez-Vega, Francisco, Kantheti, Havish S, Rojas Zamalloa, Jorge A, Krieger, Penina, Callahan, Margaret K, Betof Warner, Allison, Postow, Michael A, Momtaz, Parisa, Nair, Suresh, Ariyan, Charlotte E, Barker, Christopher A, Brady, Mary Susan, Coit, Daniel G, Rosen, Neal, Chapman, Paul B, Busam, Klaus J, Solit, David B, Panageas, Katherine S, Wolchok, Jedd D, Schultz, Nikolaus

“… Cutaneous and unknown primary melanomas frequently harbor alterations that activate the MAPK pathway. Whether MAPK driver detection beyond BRAF V600 is …”
Weitere Angaben

Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab von Friedman, Claire F, Clark, Varina, Raikhel, Andrew V, Barz, Tim, Shoushtari, Alexander N, Momtaz, Parisa, Callahan, Margaret K, Wolchok, Jedd D, Chapman, Paul B, Hellmann, Matthew D, Postow, Michael A

“… The Common Terminology Criteria for Adverse Events (CTCAE) were developed to document the adverse effects of chemotherapy but are now also used to document …”
Weitere Angaben

Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway von Postow, Michael, Momtaz, Parisa

“… T-lymphocytes have the potential to recognize cancer antigens as foreign and therefore eliminate them. However, immune checkpoints such as cytotoxic …”
Volltext

Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies von Momtaz, Parisa, Pentsova, Elena, Abdel-Wahab, Omar, Diamond, Eli, Hyman, David, Merghoub, Taha, You, Daoqi, Gasmi, Billel, Viale, Agnes, Chapman, Paul B

“… Tumor-derived cell free DNA (cfDNA) can be detected in plasma. We hypothesized that mutated BRAF V600 cfDNA could be quantified in the cerebrospinal fluid …”
Weitere Angaben

Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes von Momtaz, Parisa, O’Connor, Catherine A., Chou, Joanne F., Capanu, Marinela, Park, Wungki, Bandlamudi, Chaitanya, Berger, Michael F., Kelsen, David P., Suehnholz, Sarah P., Chakravarty, Debyani, Yu, Kenneth H., Varghese, Anna M., Zervoudakis, Alice, Li, Jia, Ku, Geoffrey Y., Park, Jennifer S., Shcherba, Marina, Harding, James J., Goldberg, Zoe, Abou‐Alfa, Ghassan K., Salo‐Mullen, Erin E., Stadler, Zsofia K., Iacobuzio‐Donahue, Christine A., O’Reilly, Eileen M.

“… Background Patients with germline/somatic BRCA1/BRCA2 mutations (g/sBRCA1/2) comprise a distinct biologic subgroup of pancreas ductal adenocarcinoma (PDAC) …”
Volltext

Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy von Atkinson, Thomas M, Hay, Jennifer L, Young Kim, Soo, Schofield, Elizabeth, Postow, Michael A, Momtaz, Parisa, Warner, Allison Betof, Shoushtari, Alexander N, Callahan, Margaret K, Wolchok, Jedd D, Li, Yuelin, Chapman, Paul B

“… Abstract Background Adjuvant anti-PD1 treatment improves relapse-free survival (RFS) but has not been shown to improve overall survival (OS) in melanoma and is …”
Volltext

Beyond the Five-Year Milestone: Long-term Survivorship of Melanoma Patients Treated Off-Trial with anti-PD-1 von Loo, Kimberly, Kalvin, Hannah L., Panageas, Katherine S., Callahan, Margaret K., Chapman, Paul B., Momtaz, Parisa, Shoushtari, Alexander N., Wolchok, Jedd D., Postow, Michael A., Warner, Allison Betof

Volltext